Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
66.93 USD | -0.56% | -1.75% | -17.38% |
Apr. 17 | UBS Adjusts Gilead Sciences Price Target to $75 From $81, Maintains Neutral Rating | MT |
Apr. 15 | Goldman Sachs Adjusts Gilead Sciences Price Target to $73 From $76 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.38% | 83.93B | |
+28.79% | 673B | |
+24.81% | 551B | |
-7.64% | 348B | |
+15.00% | 317B | |
+5.99% | 288B | |
+2.47% | 210B | |
-0.02% | 204B | |
-9.98% | 195B | |
-11.71% | 145B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences : Says Veklury Lowers Mortality Rate in COVID-19 Treatment